Clinical trials: Peanut Allergic Subjects
- Condition Peanut Allergic Subjects
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Food Hypersensitivity, Hypersensitivity
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study.
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Trial name
- NCT00850668
- Testing
- E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Allertein Therapeutics, LLC
Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA).
- Trial name
- PROTECT (NCT05476497)
- Testing
- VLP Peanut
- Where
- 10 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics